Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) announced a share buyback plan by its executives, reflecting confidence in the company's future development and long-term investment value [1] Group 1: Share Buyback Plan - The company's executives, including the general manager and several board members, plan to increase their holdings by no less than 120,000 shares within one month from the announcement date [1] - The shares to be purchased are part of the restricted stock incentive plan granted in 2022 [1] - The buyback will not have a set price range and will be executed based on stock price fluctuations and overall market trends [1]

证券代码：600557 证券简称：康缘药业 公告编号：2025-035 江苏康缘药业股份有限公司 关于公司部分董事、高级管理人员自愿增持公司股份 计划的公告 重要内容提示： 江苏康缘药业股份有限公司（以下简称"公司"）董事兼总经理杨永春先 生、董事高海鑫先生、董事陈学斌先生、副总经理刘权先生、副总经理王传磊先 生、副总经理潘宇先生基于对公司未来发展的信心以及对公司长期投资价值的认 可，计划自公告披露之日起 1 个月内，通过上海证券交易所交易系统以集中竞价 的方式，以自有资金增持公司股份数量合计不低于 12 万股。前述增持主体在本 次增持前所持股份均为公司 2022 年度限制性股票激励计划所授予的股票。 本次增持计划不设定价格区间，将根据公司股票价格波动情况及资本市 场整体趋势，择机逐步实施增持计划。 本次增持计划实施过程中，可能存在因市场情况变化或目前尚无法预判 的其他风险因素，导致增持计划延迟实施或无法完成的风险。如增持计划实施过 程中出现相关风险情形，公司将及时履行信息披露义务。 公司于近日接到部分董事、高级管理人员的通知，基于对公司未来发展的信 心以及公司长期投资价值的认可，上述主体计划以自有资金通过上 ...

Core Viewpoint - Kangyuan Pharmaceutical (600557.SH) announced that several key executives plan to increase their holdings in the company, reflecting their confidence in its future development and long-term investment value [1] Group 1 - The company's general manager, Yang Yongchun, along with other board members and vice presidents, will collectively purchase no less than 120,000 shares [1] - The share buyback will be conducted through the Shanghai Stock Exchange trading system within one month from the announcement date [1] - The executives are using their own funds for this share purchase, indicating a strong belief in the company's potential [1]

Core Viewpoint - Kangyuan Pharmaceutical announced that several directors and the general manager plan to increase their holdings in the company starting from November 10, 2025, through a centralized bidding method on the Shanghai Stock Exchange [1] Group 1 - The directors and general manager involved in the share buyback include Yang Yongchun, Gao Haixin, Chen Xuebin, Liu Quan, Wang Chuanlei, and Pan Yu [1] - The total number of shares to be purchased is no less than 120,000, with each individual committing to buy at least 20,000 shares [1] - There is no price range set for this buyback plan, and the participants have committed not to reduce their holdings during the implementation period and the statutory period [1]

Core Viewpoint - Kangyuan Pharmaceutical's stock has shown fluctuations with a year-to-date increase of 11.38%, but recent performance indicates a decline over the past 60 days by 10.82% [1] Group 1: Stock Performance - As of November 7, Kangyuan Pharmaceutical's stock price reached 15.17 CNY per share, with a trading volume of 73.44 million CNY and a turnover rate of 0.86% [1] - The stock has experienced a net outflow of 429,200 CNY from main funds, with large orders showing a buy of 11.98 million CNY and a sell of 12.21 million CNY [1] - Over the last five trading days, the stock has increased by 1.47%, while it has decreased by 1.56% over the last 20 days [1] Group 2: Financial Performance - For the period from January to September 2025, Kangyuan Pharmaceutical reported a revenue of 2.343 billion CNY, representing a year-on-year decrease of 24.66% [2] - The net profit attributable to shareholders for the same period was 200 million CNY, down 44.10% compared to the previous year [2] Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangyuan Pharmaceutical increased to 40,500, marking a rise of 17.20% [2] - The average number of circulating shares per person decreased by 14.68% to 13,969 shares [2] - The company has distributed a total of 949.8 million CNY in dividends since its A-share listing, with 345 million CNY distributed over the last three years [3]

Core Viewpoint - The company is closely monitoring the recent announcement from the National Medical Products Administration regarding the public consultation on policies related to traditional Chinese medicine injections, indicating a proactive approach to regulatory changes [2]. Company Summary - Kangyuan Pharmaceutical has acknowledged the recent draft announcement from the National Medical Products Administration and is in the process of monitoring its developments [2]. - The company's core product, Rendu Ning injection, has accumulated years of evidence regarding its clinical value, safety, and efficacy, and is included in several authoritative guidelines [2]. - The company believes that the government's initiative to advance the research and evaluation of traditional Chinese medicine injections aims to promote industry competition and high-quality development [2]. - The company plans to leverage this opportunity to continue driving technological innovation and support the sustainable development of the traditional Chinese medicine industry [2].

Core Insights - Kangyuan Pharmaceutical reported a significant decline in both revenue and net profit for the first three quarters of 2025, with revenue at 2.00 billion yuan, down 35.63% year-on-year [1] - The company faced challenges due to a complex external environment and changes in pharmaceutical industry policies, leading to a strategic adjustment in sales and increased academic promotion efforts [1] Revenue Performance - For the first three quarters of 2025, the company's total revenue was 2.343 billion yuan, a decrease of 24.59% year-on-year [1] - In Q3 2025, revenue was 701 million yuan, down 17.42% year-on-year [1] - Injection products saw a revenue drop of 31.23% to 770 million yuan, while oral products decreased by 24.24% to 1.359 billion yuan; however, external products grew by 10.38% to 186 million yuan [2] Profitability - The net profit attributable to the parent company for the first three quarters was 200 million yuan, a decline of 35.63% year-on-year [1] - In Q3 2025, the net profit was 57.27 million yuan, down 20.88% year-on-year [1] Product Performance - Sales of core products such as Heat Toxicity Ning Injection and Jin Zhen Oral Liquid declined due to fluctuations in terminal market demand [1] - The company is focusing on a specialized and academic transformation, with stable sales growth in orthopedic products like Compound Naxing Pain Relief Plaster and Waist Pain Relief Capsules [1] - The introduction of specialized agents for kidney disease has led to steady sales growth for Can Wu Yi Shen Pian [1]

Core Viewpoint - The company reported a decline in revenue and net profit for the third quarter of 2025 due to external market conditions and changes in the pharmaceutical industry policy, despite efforts to adjust sales strategies and enhance academic promotion [7][13]. Financial Performance - The company's revenue from injection products decreased by 31.23% compared to the same period last year, while the cost of sales for these products fell by 34.10%, primarily due to a decline in sales of the core product, Heat Poisoning Ning Injection [13]. Business Strategy - The company is focusing on a specialized and academic transformation, implementing line management for the marketing team, which has led to stable sales growth in orthopedic products such as Compound Nanshing Pain Relief Plaster and Waist Pain Relief Capsules [7]. - The company is enhancing customer maintenance and development through a professional academic promotion team, aiming to effectively communicate clinical research results to target doctors and healthcare professionals [7]. Market Expansion - The company is diversifying its channels in the external market, with a focus on restoring terminal sales of key products and strengthening comprehensive evaluations and graded management of agents [8]. - In the new retail sector, the company is integrating O2O, B2C self-operated, and third-party channel resources to enhance brand strength and sales through various promotional activities [8]. R&D Innovations - The company has made progress in R&D, with several new drugs approved for market, including a Class 1 new drug for treating pelvic inflammatory disease and a Class 1 innovative drug for treating atopic dermatitis [8]. - Ongoing clinical trials for innovative drugs targeting obesity and type 2 diabetes are progressing as planned, with the aim of entering Phase III clinical trials in the third quarter of 2026 [9].

Core Insights - The company reported a revenue of 701 million yuan and a net profit attributable to shareholders of 57.27 million yuan for Q3 2025, facing performance pressure due to external environment complexities and market demand fluctuations [1] - Despite challenges, the company is not slowing down its development pace and is focusing on strengthening its operational foundation for future growth [1] Academic Marketing and Product Value - The company is enhancing its academic marketing system by focusing on evidence-based research, updating academic materials, and promoting products into authoritative guidelines [2] - A total of 248 sets of academic materials have been updated, covering key product lines such as respiratory and cardiovascular diseases, which align clinical value with market needs [2] - The company has successfully integrated 10 core products into 6 authoritative guidelines, which is expected to boost prescription willingness among doctors and drive sales growth [2] Diversified Sales Channels - To mitigate risks from single-channel dependency, the company is actively developing a multi-faceted sales strategy, including agency recruitment, OTC, channel sales, and clinic distribution [3] - The company is enhancing the quality and academic promotion capabilities of its agents through standardized admission criteria and professional training [3] - In the OTC sector, the company is focusing on core products and collaborating with new retail channels to stabilize market prices while achieving success in expanding into small chain and generic drug markets [3] Operational Improvements and Future Outlook - The company is strengthening evidence-based medical support and building an academic marketing team to enhance professional and academic capabilities [4] - Despite facing performance pressure, the company is implementing precise measures to solidify its operational foundation, showing signs of marginal improvement in its fundamentals [4] - With the continued expansion of terminal coverage for core products and the gradual release of academic promotion effects, the company is expected to gradually reverse the performance volatility and achieve more stable growth [4]

Group 1 - Kanyuan Pharmaceutical (600557.SH) reported its Q3 2025 results, with 14 institutional investors holding a total of 258 million shares, representing 45.62% of the company's total equity as of October 30, 2025 [1] - The top ten institutional investors collectively hold 45.53% of the shares, with a decrease of 2.98 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, five funds increased their holdings, accounting for a 0.66% increase compared to the previous period [2] - Three new public funds disclosed their holdings this quarter, while 151 funds did not disclose their holdings again, including major ETFs and bond funds [2]